Second primary malignancies in patients with clinical T1bN0 esophageal squamous cell carcinoma after definitive therapies: supplementary analysis of the JCOG trial: JCOG0502.
Definitive chemoradiotherapy
Esophageal cancer
Esophagectomy
Second malignancies
Journal
Journal of gastroenterology
ISSN: 1435-5922
Titre abrégé: J Gastroenterol
Pays: Japan
ID NLM: 9430794
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
18
09
2021
accepted:
26
02
2022
pubmed:
14
5
2022
medline:
29
6
2022
entrez:
13
5
2022
Statut:
ppublish
Résumé
Previous studies have suggested that patients with esophageal squamous cell carcinoma (ESCC) are still at a high risk of developing second primary malignancies (SPMs) after definitive therapies. We evaluated the development of SPMs and explored its risk factors in patients with clinical T1bN0 ESCC. JCOG0502 prospectively compared esophagectomy with definitive chemo-radiotherapy for clinical T1bN0 ESCC. Here, we reviewed all JCOG0502 patients' data for SPMs and investigated the risk factors for SPMs using uni-variable and multivariable analyses by Fine and Gray model. Among 379 enrolled patients, 213 underwent esophagectomy and 166 received chemo-radiotherapy. Patient characteristics were male (85%); median age [63 (range 41-75) years; location of the primary tumor (upper/middle/lower thoracic esophagus, 11%/63%/27%, respectively]; alcohol consumption history (79%); smoking history (66%); prevalence of no/several/many/unknown Lugol-voiding lesions (LVLs) (45%/36%/8%/11%, respectively). In a median follow-up of 7.1 years, 118 SPMs occurred in 99 (26%) patients. Cumulative incidences of SPMs after 3, 5, and 10 years were 9%, 15%, and 36%, respectively. The most common primary tumor sites were the head and neck (35%), stomach (20%) and lungs (14%). In multivariable analyses, compared to no LVLs, several LVLs [hazard ratio (HR) 2.24, 95% confidential interval (CI) 1.32-3.81] and many LVLs (HR 2.88, 95% CI 1.27-6.52) were significantly associated with the development of SPMs. Sixteen patients died due to the SPMs. The incidence of SPMs was high. The presence of LVLs, which was a predictive factor for SPMs, may be useful for surveillance planning.
Sections du résumé
BACKGROUND
Previous studies have suggested that patients with esophageal squamous cell carcinoma (ESCC) are still at a high risk of developing second primary malignancies (SPMs) after definitive therapies. We evaluated the development of SPMs and explored its risk factors in patients with clinical T1bN0 ESCC.
METHODS
JCOG0502 prospectively compared esophagectomy with definitive chemo-radiotherapy for clinical T1bN0 ESCC. Here, we reviewed all JCOG0502 patients' data for SPMs and investigated the risk factors for SPMs using uni-variable and multivariable analyses by Fine and Gray model.
RESULTS
Among 379 enrolled patients, 213 underwent esophagectomy and 166 received chemo-radiotherapy. Patient characteristics were male (85%); median age [63 (range 41-75) years; location of the primary tumor (upper/middle/lower thoracic esophagus, 11%/63%/27%, respectively]; alcohol consumption history (79%); smoking history (66%); prevalence of no/several/many/unknown Lugol-voiding lesions (LVLs) (45%/36%/8%/11%, respectively). In a median follow-up of 7.1 years, 118 SPMs occurred in 99 (26%) patients. Cumulative incidences of SPMs after 3, 5, and 10 years were 9%, 15%, and 36%, respectively. The most common primary tumor sites were the head and neck (35%), stomach (20%) and lungs (14%). In multivariable analyses, compared to no LVLs, several LVLs [hazard ratio (HR) 2.24, 95% confidential interval (CI) 1.32-3.81] and many LVLs (HR 2.88, 95% CI 1.27-6.52) were significantly associated with the development of SPMs. Sixteen patients died due to the SPMs.
CONCLUSION
The incidence of SPMs was high. The presence of LVLs, which was a predictive factor for SPMs, may be useful for surveillance planning.
Identifiants
pubmed: 35546373
doi: 10.1007/s00535-022-01870-y
pii: 10.1007/s00535-022-01870-y
pmc: PMC9232445
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
455-463Subventions
Organisme : National Cancer Center Research and Development Fund
ID : 2020-J-3
Informations de copyright
© 2022. The Author(s).
Références
Gastrointest Endosc. 2002 Oct;56(4):517-21
pubmed: 12297767
Cancer Med. 2019 Oct;8(14):6414-6425
pubmed: 31475462
J Am Coll Surg. 2005 Aug;201(2):188-93
pubmed: 16038814
Carcinogenesis. 2005 May;26(5):1008-12
pubmed: 15718256
J Clin Oncol. 2003 Dec 1;21(23):4336-41
pubmed: 14645422
J Clin Invest. 1989 Jan;83(1):314-6
pubmed: 2562960
Nature. 2019 Jan;565(7739):312-317
pubmed: 30602793
Esophagus. 2019 Jul;16(3):221-245
pubmed: 31098822
Jpn J Clin Oncol. 2009 Oct;39(10):638-43
pubmed: 19549720
Dis Esophagus. 2014 Jul;27(5):457-62
pubmed: 23009284
Gastroenterology. 2016 Nov;151(5):860-869.e7
pubmed: 27492616
Cancer Med. 2020 Jan;9(1):394-400
pubmed: 31730285
Int J Clin Oncol. 2018 Aug;23(4):652-658
pubmed: 29520523
Gastroenterology. 2018 Jan;154(2):360-373
pubmed: 28823862
Asian Pac J Cancer Prev. 2014;15(2):1023-9
pubmed: 24568445
Jpn J Clin Oncol. 2020 Sep 28;50(10):1162-1167
pubmed: 32533160
Gastroenterology. 2019 Aug;157(2):382-390.e3
pubmed: 31014996
Cancer Sci. 2010 Apr;101(4):1001-6
pubmed: 20085588
Ann Oncol. 2019 Jan 1;30(1):34-43
pubmed: 30475943
Cancer. 2004 Sep 15;101(6):1375-81
pubmed: 15368325
PLoS One. 2015 Jan 30;10(1):e0116384
pubmed: 25635388
Gastroenterology. 2021 Dec;161(6):1878-1886.e2
pubmed: 34389340
Dis Esophagus. 2012 Aug;25(6):505-11
pubmed: 22067063
Cancer. 1953 Sep;6(5):963-8
pubmed: 13094644
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1543-9
pubmed: 18559572
Gut. 2010 Jan;59(1):39-48
pubmed: 19828467
Tumori. 2015 May-Jun;101(3):328-33
pubmed: 25908032
Br J Cancer. 2001 Nov 30;85(11):1700-5
pubmed: 11742491
Dis Esophagus. 2020 Sep 4;33(9):
pubmed: 32052025
BMC Cancer. 2017 Jan 13;17(1):54
pubmed: 28086818